Researchers show that a hormone secreted into the blood during endurance or aerobic exercise reduces the protein levels associated with Parkinson's disease and prevents the exercise problem in mice .
Johns Hopkins Medical Group September 12th
Johns Hopkins Medicine and the Dana-Farber Cancer Institute in Boston show that a hormone secreted into the blood during endurance or aerobic exercise can lower protein levels associated with Parkinson's disease and prevent exercise problems in mice.
Parkinson's disease is a neurological disease that causes people to lose control of muscles and movement . In , the United States affects about 1 million people.
If confirmed in further laboratory studies and clinical trials, the researchers' studies of mice with Parkinson's disease symptoms may pave the way for Parkinson's disease treatment based on the hormone Irisin . The research results were recently published in the Proceedings of the National Academy of Sciences.
study was published on August 31, 2022 in the journal Proceedings of the National Academy of Sciences (Latest Impact Factor: 12.779)
MD, Johns Hopkins Medical Group, and Dr. Bruce Spiegelman of the Dana-Farber Cancer Institute jointly studied the link between the motor molecule irisin and Parkinson's disease .
Ted Dawson Professor
For a long time, people have found that Endurance exercise can relieve the symptoms of Parkinson's disease, but the cause is unknown . Dawson's research focuses on neurodegenerative diseases, including Parkinson's disease, and he says the first clue to the link between exercise, Parkinson's disease and irisin comes from Spiegelman, whose first paper on irisin was published in the 2012 journal Nature , followed by other scientific journals, showing that , a protein called an irisin peptide, is released into the bloodstream and increases with endurance exercise.
Previous research was published on January 11, 2012 in the journal Nature (Latest Impact Factor: 69.504)
Bruce Spiegelman Dr.
In the past decade, other laboratories have found that exercise will increase irisin levels, and people are interested in the link between irisin and Alzheimer's disease and Parkinson's disease.
To test the effect of irisin on Parkinson's disease , Dawson and Spiegelman's team started with a research model used by Dawson, in which mouse brain cells were designed to disperse α-synuclein (a protein associated with the brain neurotransmitter dopamine that regulates emotions and movement) .
When α-synuclein aggregates, these aggregations kill brain cells that produce dopamine , a key trigger for Parkinson's disease . Dawson said the fibrous clumps of α-synuclein are very similar to those found in the brains of Parkinson's patients.
In a laboratory model, researchers found that irisin can prevent the accumulation of α-synuclein clumps and its associated brain cell death .
Next, the research team tested the effect of irisin on mice designed to have Parkinson-like symptoms . They injected α-synuclein into the striatum in the mouse brain, which is the region of the dopamine-producing neurons . Two weeks later, , researchers injected mice with a viral vector . This viral vector can increase the level of irisin in the blood , which can pass through the blood-brain barrier. Six months later, , mice receiving irisin did not have muscle motor defects, while mice injected with placebo showed defects in grip and ability to drop .
Further study of Irisin-administered mouse brain cells showed that motor hormone can reduce Parkinson's disease-related α-synuclein levels by 50% to 80% . The team also demonstrated that irisin can also accelerate the transport and degradation of α-synuclein by fluid-filled capsules (called lysosomes) in brain cells.
"If the utility of irisin is successful, we can imagine it being developed into a gene or recombinant protein therapy ," said Dawson, referring to , which aims to use cell genetics to treat diseases, the drug development field that is constantly expanding in . Dawson is the director of Leonard and Madlyn Abramson, Professor of Neurology and Director of Neurology, , Johns Hopkins University School of Medicine (JHUSOM) , Institute for Cell Engineering, (ICE).
"Given that irisin is a naturally occurring peptide hormone and appears to have evolved to cross the blood-brain barrier, we believe it is worthwhile to continue to evaluate irisin as a potential treatment for Parkinson's disease and other forms of neurodegenerative diseases ," Spiegelman added.
Dawson and Spiegelman have applied for the application patent of irisin in Parkinson's disease . Spiegelman founded a biotech company called Aevum Therapeutics Inc. in Boston , and plans to develop irisin into a drug for treating neurodegenerative diseases .
This article is collected and compiled from the Internet and is only used for popular science. It involves disease diagnosis, treatment, rehabilitation, etc. Please be sure to go to the hospital for treatment and seek professional advice.
